nach oben

memo - Magazine of European Medical Oncology

Erschienen in:

27.10.2023 | case report

Fifth-line HER2-directed therapy for metastatic adenocarcinoma of the gastroesophageal junction

A case report

verfasst von: Sophie Roider-Schur, Sybille Machat, Leopold Öhler

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 4/2023

Einloggen, um Zugang zu erhalten

Summary

Evaluation of HER2 status and programmed death-ligand 1 (PD-L1) combined positive score (CPS) is mandatory in all patients with HER2-positive metastatic adenocarcinoma of the gastroesophageal junction (GEJ) not only to tailor first-line therapy but also to improve individual survival outcome. However, despite advances in the therapeutic management of metastatic adenocarcinoma of the GEJ, prognosis of these patients remains poor. We report a patient with HER2-positive metastatic adenocarcinoma of the GEJ who showed significant clinical and radiological benefit to HER2-directed therapy in the fifth-line therapeutic setting.

Vorheriger Artikel Second-line treatment of HER2-positive advanced gastroesophageal adenocarcinoma

Nächster Artikel Comment to Smith MR, Hussain M, Saad F et al. (2022, N Engl J Med) Darolutamide and survival in metastatic, hormone-sensitive prostate cancer

Trastuzumab deruxtecan in patients in the USA and Europe with HER2-positive advanced gastric or gastroesophageal junction cancer with disease progression on or after a trastuzumab-containing regimen (DESTINY-Gastric02): primary and updated analyses from a single-arm, phase 2 study. Lancet Oncol. 2023;24(7):744–56. https://doi.org/10.1016/S1470-2045(23)00215-2.

Gastric cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up. Ann Oncol. 2022;33(10):1005–20. https://doi.org/10.1016/j.annonc.2022.07.004.

Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010;376(9742):687–97. https://doi.org/10.1016/S0140-6736(10)61121-X.

Randomized, phase II study of trastuzumab beyond progression in patients with HER2-positive advanced gastric or gastroesophageal junction cancer: WJOG7112G (T-ACT study). J Clin Oncol. 2020;38(17):1919–27. https://doi.org/10.1200/JCO.19.03077.

Gastric cancer. Lancet. 2020;396(10251):635–48.

Trastuzumab deruxtecan in previously treated HER2-positive gastric cancer. N Engl J Med. 2020;382(25):2419–30. https://doi.org/10.1056/NEJMoa2004413.

First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. Lancet. 2021;398(10294):27–40.

Pembrolizumab plus chemotherapy versus chemotherapy alone for first-line treatment of advanced oesophageal cancer (KEYNOTE-590): a randomised, placebo-controlled, phase 3 study. Lancet. 2021;398(10302):759–71. https://doi.org/10.1016/S0140-6736(21)01234-4.

The KEYNOTE-811 trial of dual PD‑1 and HER2 blockade in HER2-positive gastric cancer. Nature. 2021;600(7890):727–30. https://doi.org/10.1038/s41586-021-04161-3.

10.

Lorenzen S, Thuss-Patience PC, Pauligk C, et al. FOLFIRI plus ramucirumab versus paclitaxel plus ramucirumab for patients with advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction as second-line therapy: Interim safety and efficacy results from the phase II RAMIRIS Study (AIO-STO-0415) of the German Gastric Group at AIO. J Clin Oncol. 2019;37:4023.CrossRef

11.

HER2 expression, test deviations, and their impact on survival in metastatic gastric cancer: results from the prospective multicenter VARIANZ study. J Clin Oncol. 2021;39(13):1468–78. https://doi.org/10.1200/JCO.20.02761.

Titel: Fifth-line HER2-directed therapy for metastatic adenocarcinoma of the gastroesophageal junction
A case report
verfasst von: Sophie Roider-Schur
Sybille Machat
Leopold Öhler
Publikationsdatum: 27.10.2023
Verlag: Springer Vienna
Erschienen in: memo - Magazine of European Medical Oncology / Ausgabe 4/2023
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI: https://doi.org/10.1007/s12254-023-00928-8

Springer Medizin Österreich

Summary

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2023

Focal therapy in intermediate- and high-risk prostate cancer

Supportive management

WNT3 and LEF1 as markers for diagnosis and survival prediction in chronic lymphocytic leukemia patients

ASCO 2023: new treatment options in CNS tumors

Second-line treatment of HER2-positive advanced gastroesophageal adenocarcinoma

Challenges in prevention, early detection, and management of febrile neutropenia in adult patients with solid tumors